Drug use evaluation of prothrombin complex concentrate based on weighted TOPSIS method
10.19960/j.issn.1005-0698.202312003
- VernacularTitle:基于加权TOPSIS法的人凝血酶原复合物的药物利用评价
- Author:
Bo ZHANG
1
;
Li LI
;
Qi YAN
;
Shi-Cai CHEN
;
Jin-Hua ZHANG
Author Information
1. 徐州医科大学附属医院药学部(江苏徐州 221006)
- Keywords:
Prothrombin complex concentrate;
Weighted TOPSIS method;
Attribute hierarchical model;
Drug use evaluation
- From:
Chinese Journal of Pharmacoepidemiology
2023;32(12):1338-1346
- CountryChina
- Language:Chinese
-
Abstract:
Objective To establish the detailed rules for the drug use evaluation(DUE)of prothrombin complex concentrate(PCC),and evaluate the use of PCC by weighted TOPSIS method to provide references for its clinical rational application.Methods Based on the instructions of PCC and referring to relevant data,the DUE standard rules were established,and weighted TOPSIS method was used to evaluate the rationality of medication in the cases of in patients who used PCC from January 2021 to December 2021 in the Affiliated Hospital of Xuzhou Medical University.Results A total of 121 cases were included,the relative weights of the three indicators were as follows:coagulation function,dosage,interval,course of treatment and,diagnosis,progress notes drug interaction,with the weights of 0.095 2,0.0913,0.091 3,0.091 3,0.089 7,0.084 1 and 0.081 7 respectively.There were 21 cases(17.36%)with reasonable medical records,39 cases(32.23%)with basically reasonable medical records,and 61 cases(50.41%)with unreasonable medical records.The main unreasonable problems were manifested in indications,usage and dosage,and drug interaction.Conclusion The DUE criteria of PCC established is more scientific,practical and feasible.The indications,usage,dosage,and drug interaction of PCC remain unreasonable criteria,and pharmaceutical intervention should be carried out to promote its rational use.
